integrity applications is dedicated to developing breakthrough innovations in non-invasive glucose monitoring devices. since its founding in 2001, integrity applications has been committed to improving the quality of life for people with diabetes by removing the obstacles of traditional invasive devices, namely painful pricking of fingertips, added costs as a result of disposables, as well as inconvenience. integrity applications has developed a state-of-the-art way to measure glucose levels using three non-invasive technologies, ultrasound, thermal, and electromagnetic in combination with a proprietary algorithm to produce a weighted glucose measurement. after proof of concept in 2002, integrity applications developed the first working prototype, glucotrack in august 2003. glucotrack® model df-f received ce mark approval in june 2013 and kfda in march 2016. glucotrack is currently being marketed in the european union and in south korea. the company went public in november 2011 and is
Company profile
Ticker
GCTK
Exchange
Website
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
Former names
Integrity Applications, Inc.
SEC CIK
Corporate docs
IRS number
980668934
GCTK stock data
Latest filings (excl ownership)
DEF 14A
Definitive proxy
1 Apr 24
10-K
2023 FY
Annual report
28 Mar 24
PRE 14A
Preliminary proxy
22 Mar 24
8-K
Completion of Acquisition or Disposition of Assets
16 Feb 24
8-K
Regulation FD Disclosure
11 Jan 24
8-K
Glucotrack Announces Early Accuracy Data for Its Implantable Continuous Glucose Monitor
2 Jan 24
8-K
GLUCOTRACK ANNOUNCES 180-Day Extension to Regain Compliance with Nasdaq Minimum Bid Price Requirement
30 Nov 23
10-Q
2023 Q3
Quarterly report
14 Nov 23
8-K
Glucotrack Announces Preclinical Testing with Implantable Continuous Glucose Monitor
13 Oct 23
8-K
Departure of Directors or Certain Officers
12 Oct 23
Latest ownership filings
SC 13G
SABBY MANAGEMENT, LLC
3 Jan 24
3
James S Cardwell
18 Oct 23
3
Erin Catherine Carter
11 Sep 23
3
Allen Danzig
10 Aug 22
SC 13D
Beneficial ownership report
25 Feb 20
3
Shimon D Rapps
14 Aug 19
3
DREW SYCOFF
19 Jul 19
4
david podwalski
28 Jun 17
3
david podwalski
28 Jun 17
4/A
Robert Fischell
9 Jun 17
Financial summary
Quarter (USD) | Sep 23 | Jun 23 | Mar 23 | Dec 22 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 22 | Dec 21 | Dec 20 | Dec 19 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
---|---|---|---|---|---|---|
Cash on hand (at last report) | 6.90 mm | 6.90 mm | 6.90 mm | 6.90 mm | 6.90 mm | 6.90 mm |
Cash burn (monthly) | 629.00 k | (no burn) | 741.33 k | 497.83 k | 626.67 k | 423.92 k |
Cash used (since last report) | 4.17 mm | n/a | 4.91 mm | 3.30 mm | 4.15 mm | 2.81 mm |
Cash remaining | 2.73 mm | n/a | 1.98 mm | 3.60 mm | 2.74 mm | 4.09 mm |
Runway (months of cash) | 4.3 | n/a | 2.7 | 7.2 | 4.4 | 9.6 |
Institutional ownership, Q2 2023
8.0% owned by funds/institutions
13F holders | Current |
---|---|
Total holders | 5 |
Opened positions | 4 |
Closed positions | 2 |
Increased positions | 1 |
Reduced positions | 0 |
13F shares | Current |
---|---|
Total value | 742.63 mm |
Total shares | 2.15 mm |
Total puts | 0.00 |
Total calls | 0.00 |
Total put/call ratio | – |
Largest owners | Shares | Value |
---|---|---|
Sabby Management | 2.03 mm | $701.53 mm |
Alerus Financial Na | 69.28 k | $23.91 mm |
Warberg Asset Management | 30.00 k | $10.35 mm |
Two Sigma Securities | 19.03 k | $6.57 mm |
UBS UBS Group AG - Registered Shares | 800.00 | $276.00 k |
Proequities | 0.00 | $0.00 |
News
Glucotrack Announces Expansion Of Its Continuous Glucose Monitoring Technology To Epidural Glucose Monitoring
16 Apr 24
12 Health Care Stocks Moving In Monday's Pre-Market Session
8 Apr 24
12 Health Care Stocks Moving In Friday's Intraday Session
5 Apr 24
Glucotrack Announces Increased Sensor Longevity For Its Implantable Continuous Blood Glucose Monitor
2 Apr 24
12 Health Care Stocks Moving In Wednesday's After-Market Session
28 Feb 24
Press releases
GLUCOTRACK ANNOUNCES EXPANSION OF ITS CONTINUOUS GLUCOSE MONITORING TECHNOLOGY TO EPIDURAL GLUCOSE MONITORING
16 Apr 24
Presenting on the Emerging Growth Conference 69 Day 1 on April 3 Register Now
2 Apr 24
GLUCOTRACK EXPANDS LEADERSHIP TEAM WITH NEW VICE PRESIDENT OF QUALITY
12 Mar 24
GLUCOTRACK ANNOUNCES THE APPOINTMENT OF LUIS MALAVÉ TO CHAIR OF THE BOARD OF DIRECTORS
13 Feb 24